Correction

Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study (vol 8, e002012, 2022)

RMD OPEN (2023)

Volume 9, Issue 2, Pages -

DOI: 10.1136/rmdopen-2021-002012corr1

Click your name to claim this paper and add it to your profile.